GlassScriptPhysician profile
Christopher A Gisler
NPI 1588845796
$757,131.95
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $166K · 2020: $46K · 2021: $44K · 2022: $171K · 2023: $300K · 2024: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $136K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $121K · Travel and Lodging: $45K · Consulting Fee: $16K · Food and Beverage: $11K · Education: $181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $135,922.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $121,052.74 |
| Travel and Lodging | $45,364.70 |
| Consulting Fee | $16,299.83 |
| Food and Beverage | $11,125.43 |
| Education | $181.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $238,090.58 | 2021-2023 | Krystexxa |
| Vifor Pharma, INC. | $145,930.72 | 2019-2024 | Veltassa, Korsuva |
| Amgen INC. | $120,531.08 | 2019-2024 | Krystexxa, Tavneos, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $83,338.08 | 2021-2024 | |
| Akebia Therapeutics INC | $60,208.87 | 2019-2024 | Auryxia |
| Travere Therapeutics, INC. | $50,848.29 | 2022-2024 | |
| Calliditas Therapeutics US INC. | $35,061.78 | 2022-2024 | Tarpeyo |
| Otsuka America Pharmaceutical, INC. | $18,595.94 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $1,404.99 | 2019-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $1,188.00 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $462.85 | 2019-2024 | Farxiga, Lokelma |
| Opko Pharmaceuticals, LLC | $287.40 | 2019-2023 | Rayaldee |
| C. R. Bard, INC. & Subsidiaries | $196.67 | 2020 | |
| Alexion Pharmaceuticals, INC. | $193.03 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $187.68 | 2022-2023 | Purified Cortrophin Gel |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Enterprises LLC | $173.15 | 2019 | |
| Ardelyx, INC. | $106.88 | 2024 | Xphozah 30 Mg |
| Aurinia Pharma U.S., INC. | $95.44 | 2021-2022 | |
| Daiichi Sankyo INC. | $51.59 | 2023 | Injectafer |
| Novartis Pharmaceuticals Corporation | $48.32 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $39.22 | 2020-2022 | |
| Covidien LP | $25.53 | 2019 | |
| Genzyme Corporation | $19.36 | 2019 | |
| Medtronic USA, INC. | $16.94 | 2020 | |
| Mallinckrodt Hospital Products INC. | $16.67 | 2020 | |
| Boston Scientific Corporation | $12.89 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Gisler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.